Novartis AG (NYSE: NVS) said that Kesimpta (ofatumumab) had won European Union approval as the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple

Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis

01:21am, Tuesday, 30'th Mar 2021

Company Announcement

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

11:19am, Monday, 29'th Mar 2021

Media Release Copenhagen, Denmark, March 29, 2021

Transactions in connection with share buy-back program

03:12am, Monday, 29'th Mar 2021

Company Announcement

Transactions in connection with share buy-back program

05:15am, Monday, 22'nd Mar 2021

Company Announcement

Transactions in connection with share buy-back program

04:46am, Monday, 15'th Mar 2021

Company Announcement

Genmab Announces Preclinical Data to be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021

05:37pm, Wednesday, 10'th Mar 2021

Media Release

Notice to Convene the Annual General Meeting of Genmab A/S

04:14am, Tuesday, 09'th Mar 2021

Company Announcement

Transactions in connection with share buy-back program

03:54am, Monday, 08'th Mar 2021

Company Announcement

Genmab: A Company With Downside Antibodies

03:28pm, Sunday, 07'th Mar 2021

The company looks financially strong regardless of which angle it is analyzed from

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

06:39am, Sunday, 07'th Mar 2021

Company Announcement

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

03:31pm, Tuesday, 02'nd Mar 2021

Company Announcement

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by